drugset / Trial / NCT00365456
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
RandomizedSingle-groupOpen-labelTreatment
Summary
The objective is to show superior efficacy of PTH (1-84) over risedronate in treating osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12 months followed by 12 months treatment with risedronate.
Timeline
- Start
- 2006-07
- Primary completion
- 2011-01
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Parathyroid Hormone | Protein / enzyme biologic | 100 ug | Subcutaneous |
| Comparator | Risedronate | Small molecule | 35 mg | Oral |